Ishita Drugs & Indus Intrinsic Value
Ishita Drugs & Indus intrinsic value. Ishita Drugs & Indus (ISHITADR) median intrinsic value is ₹46.48 from 9 valuation models (range ₹24–₹181), vs current price ₹79.83 — -41.8% downside (Trading Above Calculated Value), margin of safety -71.8%. For current market price and key ratios, visit Ishita Drugs & Indus share price today.
ISHITADR Valuation Methods Summary — DCF, Graham Number & P/E
Ishita Drugs & Indus intrinsic value across 9 models vs current price ₹79.83 — upside/downside and value range per method. Compare with ISHITADR fair value estimate to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹52.80 | ₹42.24 - ₹63.36 | -33.9% | EPS: ₹2.40, Sector P/E: 22x |
| Book Value Method | asset | ₹80.00 | ₹72.00 - ₹88.00 | +0.2% | Book Value/Share: ₹40.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹86.67 | ₹78.00 - ₹95.34 | +8.6% | Revenue/Share: ₹43.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹33.33 | ₹30.00 - ₹36.66 | -58.2% | EBITDA: ₹1.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹181.11 | ₹144.89 - ₹217.33 | +126.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹23.95 | ₹21.55 - ₹26.35 | -70.0% | EPS Growth: 5.6%, Fair P/E: 4.5x |
| Growth Adjusted P/E | growth | ₹36.36 | ₹32.72 - ₹40.00 | -54.5% | Revenue Growth: 2.0%, Adj P/E: 15.2x |
| ROE Based Valuation | profitability | ₹39.91 | ₹35.92 - ₹43.90 | -50.0% | ROE: 8.3%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹46.48 | ₹41.83 - ₹51.13 | -41.8% | EPS: ₹2.40, BVPS: ₹40.00 |
ISHITADR Intrinsic Value vs Market Price — All Valuation Models
Ishita Drugs & Indus fair value range ₹24–₹181 vs current market price ₹79.83 across 9 valuation models. Read ISHITADR dividend history for the complete payout history and dividend yield track record.
ISHITADR Intrinsic Value Analysis — Undervalued or Overvalued?
Ishita Drugs & Indus median intrinsic value ₹46.48, current price ₹79.83 — Trading Above Calculated Value by 41.8%, margin of safety -71.8%.
What is the intrinsic value of ISHITADR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Ishita Drugs & Indus (ISHITADR) is ₹46.48 (median value). With the current market price of ₹79.83, this represents a -41.8% variance from our estimated fair value.
The valuation range spans from ₹23.95 to ₹181.11, indicating ₹23.95 - ₹181.11.
Is ISHITADR undervalued or overvalued?
Based on our multi-method analysis, Ishita Drugs & Indus (ISHITADR) appears to be trading above calculated value by approximately 41.8%.
ISHITADR Financial Health — Key Ratios vs Industry Benchmarks
Ishita Drugs & Indus financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 8.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 6.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.00x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ISHITADR Cash Flow Quality — Operating & Free Cash Flow
Ishita Drugs & Indus operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹-4 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |